This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Kimberly-Clark stock has declined over 10% so far in 2018. Negative sentiment is fueled by rising raw materials costs.
Kimberly-Clark Corporation (KMB - Free Report) is slated to release second-quarter 2018 results on Jul 24. This consumer goods company has a mixed record of earnings surprises in the trailing four quarters. Let’s see how things are placed ahead of the upcoming quarterly results. Will Cost-Cutting & Other Efforts Fuel Q2 Performance? Kimberly-Clark has been quite keen on reducing costs through its Focus on Reducing Costs Everywhere program or FORCE.
GEC GE KMB.WI GNE KMB KCDMY SAM BGS
41 of 53 S&P 500 Dividend Aristocrats stocks were deemed "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields 7/9/18.
GD KMB SWK PEP JNJ CINF CVX ITW DOV ABBV ABBV LEG MCD
The average retirement lasts for 18 years in the United States. Hence, when investing for retirement, investors need to consider how inflation will affect their income. Allocations into retirement stocks should be set with income in mind.
FOJCF O.PRF O CSL OPRF KMB KCDMY NNN.PRD NNN.PRF NNN.PRE FOJCY T KMB.WI TROW ABBV CFR MCD NNN ABBV
Discussion: Eagle Pharmaceuticals Inc. (EGRX) is a specialty pharmaceutical company focused on developing and commercializing injectable products for oncology and critical care segments. The lead candidate of the company, Bendeka (bendamustine hydrochloride), received the U.S. Patent No. 10,010,533. The patent covers the drug’s use in blood cancer. The IP of the company now goes up to 15 patents. Teva Pharma (NYSE:TEVA) owns exclusive U.
OCUL ASLN EGRX ATBPF SRNE TEVA TTNP KMB AVXL ATE
MEXICO CITY (Reuters) - Mexico’s business elite had warm words for president-elect Andres Manuel Lopez Obrador on Wednesday after he assured them he respected private enterprise, in contrast to jibes in the campaign that some tycoons belonged to a “mafia of power.”
KMB.WI KCDMY KMB
Here we are with another installment of my "stock considerations" for the upcoming month. With the first week of trading upon us in July, it is time, once again, to lay out a plan for my potential stock pick(s) for the month. As many of you already know, I make sure to purchase at least one stock every single month, no matter where we are in a business or macroeconomic cycle. The goal of every long-term dividend growth investor is to remain consistent with their buys and try not to attempt to time the market and wait for the "best" possible time to invest.
SOJA HCN PM GIS HCP WELL.PRI LTC SBRA WELL CAH ED JCI SBRAP VTR SO GE GEC D HCN.PRJ KMB HCN.PRI PEP KHC GNE SBUX CLX
32 of 86 top yield Consumer Defensive stocks were tagged "safer" because they showed positive annual-returns, and free cash-flow yields greater than their dividend yields.
PM BUD TATYY WHGRF SLCJY AHBIF BATS 4162 KMB WHGLY WGHPY SLCJF
The last time I made two buy tranches in any one month was back in February of this year. I guess seeing the market continue on its volatile trajectory prompted me to make additional buys before June officially expires. On another note, my broker ShareBuilder, formerly ING, formerly CapitalOne Investing, has been acquired by E-Trade, and before the assets are moved over later this year, it was announced that all dividend reinvestment will be suspended along with ShareBuilder Investment Plans in July.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to KMB / Kimberly-Clark Corp. on message board site Silicon Investor.
|Kimberly-Clark Corp. (NYSE:KMB)|
as of ET